18F-FDGPET/CT与传统影像检查寻找骨转移瘤原发灶的比较

[目的]比较18F-FDG PET/CT与传统影像检查(胸片、彩超、CT及MRI等)为骨转移瘤患者寻找原发灶的临床价值.[方法]回顾性分析37例于2008年5月～2010年6月间本中心收治的经病理证实的骨转移瘤患者的病例资料,并随访其后续的诊治情况.以病理结果或临床随访作为原发灶确认标准.并将PET/CT与传统影像检查对原发灶的检出情况进行比较.且对治疗方案的调整进行汇总.[结果]37例患者中,PET/CT提示原发灶28例,其中正确检出原发灶27例(73％),1例为假阳性;传统影像检查正确检出原发灶17例(46％),两者原发灶正确检出率的差异有显著性(x2=5.61,P=0.018).27例经PET/CT正确检出原发灶的病例中,17例(63％)采取了针对原发灶的治疗措施.此外9例PET/CT未提示原发灶的患者中,3例经病理证实为假阴性.[结论]与传统影像检查相比,18F-FDG PET/CT可更有效、更便捷的找出骨转移瘤患者原发灶,进而为制定更合理的治疗方案提供依据.     

11C-胆碱PET/CT显像在前列腺癌诊断中的应用价值

目的探讨11C-胆碱PET/CT显像在前列腺癌诊断中的临床价值。方法42例PSA升高的可疑前列腺癌患者为研究组,5例浸润性膀胱癌患者为阴性对照组,静脉注射7.4 MBq/kg 11C-胆碱5 min后行仰卧位盆腔PET/CT显像,可疑转移者行全身显像。测量最高标准化摄取值(SUVmax)并计算前列腺病灶与肌肉组织SUVmax的比值T/B。结果经病理证实为前列腺癌者22例,良性前列腺增生(BPH)者25例(含对照组),两者的T/B值分别为4.32±1.35和1.68±1.23.差异有统计学意义(P<0.01)。11C-胆碱PET/CT显像诊断前列腺癌的敏感性为81.8%(18/22),特异性为84.0%(21/25)。PET/CT显示9例前列腺癌患者伴骨和(或)淋巴结及肺转移。22例前列腺癌者SUVmax与PSA值、Gleason评分值无相关性(P>0.05)。结论11C-胆碱PET/CT显像对前列腺癌的诊断有重要价值。     

PET/CT在胰头肿块型良恶性病变的鉴别诊断和在术前评估胰腺癌切除的可行性

目的 1、探讨PET/CT在胰腺癌与肿块型胰腺良病史鉴别诊断方面的价值。2、PET/CT对胰腺癌可行性切除评估中的价值。3、PET/CT在发现淋巴结转移,神经束膜侵犯和远处转移方面的价值。方法本文对37例经B超、CT、内镜等检查发现胰头占位但未能明确肿块性质的患者进行PET/CT扫描。收集病灶的大小、部位,局部和远处淋巴结转移状况,神经束膜侵犯情况,病变与邻近组织器官的解剖学关系以及是否出现远处转移病灶等情况;测量肿瘤大小及面积,病灶的18FSG早期最大标准化摄取值（SUVmax）。结果 24例术前考虑胰腺癌患者早期SUVmax平均值为6.38±3.84;肿瘤的大小平均3.40cm×2.64cm,假阳性4例;慢性胰腺炎7例早期SUVmax平均值为3.30±2.27;肿瘤的大小平均3.7cm×2.5cm。2例壶腹部癌患者SUVmax分别是5.4和4.2,肿瘤大小分别是：4.2cm×3.8cm和2.7cm×1.9cm;2例胰腺粘液性囊腺瘤,SUVmax分别是：0.6和0.8,肿瘤大小分别是：3.8cm×2.5cm和5.4cm×2.7cm。1例胰腺实性-假乳头状瘤,SUVmax值为6.9,肿瘤大小为6.6×4.7cm。1例十二指肠乳头癌,其SUVmax为6.9,肿瘤大小1.7cm×1.4cm。以早期SUVmax等于3.0作为胰腺良恶性病变的鉴别阈值,PET/CT诊断胰腺癌敏感度、特异性和准确性分别为87.1%（27/31例）、83.3%（5/6例）、86.5%（32/37）。PET/CT发现5例胰腺癌存在远处转移而无法施行手术治疗。结论 PET/CT显像诊断胰腺癌灵敏度、特异性以及准确性较高,在胰头癌和肿块型慢性胰腺炎的鉴别诊断中具有显著意义,并在术前胰腺癌可切除性评估起到指导性意义。     

18F-脱氧葡萄糖正电子发射计算机断层显像CT检查在前列腺癌诊断和分期中的应用价值

目的 评价18F-脱氧葡萄糖(18F-FDG)正电子发射计算机断层显像CT检查(PET/CT)在前列腺癌诊断和分期中的应用价值.方法 经手术或穿刺活检病理证实为前列腺癌患者40例,年龄52 ～ 78岁,平均67岁.其中T24例,T316例,T420例.行18F-FDG PET/CT及99Tcm-MDPECT骨显像检查,统计PET/CT显像对前列腺癌原发灶、淋巴结转移及骨转移诊断的敏感性,对比分析PET/CT显像及99Tcm-MDPECT骨显像对骨转移的诊断效果.结果 40例患者中,18F-FDG PET/CT检查显示前列腺局部结节状放射性浓聚17例,对原发灶诊断敏感性为43％.17例淋巴结转移患者中CT检查发现8例,18F-FDG PET/CT检查发现15例,诊断敏感性为88％,其中5例患者因PET/CT检查改变了临床分期以及治疗方案.18F-FDG PET/CT对骨转移诊断的敏感性与99Tcm-MDP骨显像相近,但特异性(95％)和准确率(96％)均明显高于99Tcm-MDP骨显像,其中6例患者因PET/CT检查改变了临床分期,2例改变了治疗方案.结论 18F-FDG PET/CT对前列腺癌淋巴结转移和骨转移有较高诊断价值,对前列腺的分期具有特殊优势,可为临床医生制定治疗方案提供可靠依据.     

探寻18F-FDG PET/CT显像在浆细胞骨髓瘤诊断中的应用价值

目的探讨浆细胞骨髓瘤的18F-FDG PET/CT影像表现及鉴别诊断。方法回顾性分析2009-2014年间我院行PET/CT检查后,并经临床确诊的36例浆细胞骨髓瘤。结果 PET显像病灶SUV最大值2.04~10.41不等,平均值为4.88,其中SUV最大值≤5.0的20例、SUV最大值5~10的15例、SUV最大值≥10的1例,病灶SUV最大值≤5.0的发生率与其他区间差异具有统计学意义(P0.05)。所有患者均未见髓外组织浸润。结论 18F-FDG PET/CT对于诊断浆细胞骨髓瘤是一项非常有用的技术。     

甲状旁腺腺瘤继发甲状旁腺功能亢进症PET/CT显像1例

患者 男,43岁。腰腿痛3～4年,CT发现多发骨质破坏,ECT发现多部位骨盐代谢异常增高,诊断为骨转移瘤,为寻找原发灶行PET／CT检查。外院右侧胫骨穿刺活检病理诊断：考虑甲状旁腺功能亢进症继发性骨病变或巨细胞瘤,不排除骨转移瘤。PET／CT示左侧甲状腺下极后方可见2．5cm×2．0cm的低密度（与肌肉比较）结节,边界清晰,密度均匀,     

18^F-FDG PET-CT对结直肠癌原发灶检出的临床评价

目的探讨PET-CT对结直肠癌病灶检出的临床应用价值。方法回顾性分析2007年4月至2008年6月23例结直肠癌的PET-CT和肠镜检查、手术及病理检查的临床资料。结果23例患者均为PET-CT首先检出结直肠癌。其PET-CT表现：CT表现为结直肠的局限性肿块、肠壁增厚或结节。PET表现为结节状或团块状局限性浓聚灶,标准摄取值（SUVmax）为11．7±9．5;延迟采集SUVmax为14.8±11．0;肿块越大,SUVmax越高,最高可达44．8。病灶部位：回盲部5例,升结肠4例,横结肠2例,降结肠2例,乙状结肠4例,直肠6例。结肠外表现：远处单器官或多器官转移者15例。结论PET-CT能较敏感地检出结直肠癌原发灶及转移灶。     

慢性肿块型胰腺炎的18F-FDG PET/CT影像学表现

目的探讨慢性肿块型胰腺炎18F-FDG PET/CT影像学表现。方法回顾性分析6例经手术病理证实的慢性肿块型胰腺炎的18F-FDG PET/CT影像资料和临床资料。结果 6例共检出6个病灶,3个位于胰头,3个位于胰尾;平均大小3.0cm×2.7cm。CT平扫6个病灶呈均匀等密度,未见钙化灶,平均CT值约为36HU;增强扫描全部病灶呈延迟期强化。全部病灶18F-FDG摄取呈局灶性增高,最大标准摄取值（SUVmax）1.6～5.3,平均SUVmax3.92±1.49,高于正常胰腺组织的2.05±0.39（t=-3.648,P=0.015）。3例病灶累及胰头,胆总管及胰管不同程度扩张,呈双管征,胰体尾部轻度萎缩;3例病灶累及胰尾,胆总管及胰管未见扩张,胰体尾部未见萎缩。病灶邻近的主要血管均未受侵。全部病例胰周及腹膜后淋巴结未见18F-FDG局灶性摄取增高,未见远处脏器或（和）组织转移。结论 18 F-FDG PET/CT对诊断慢性肿块型胰腺炎具有一定价值。     

18F-FDG PET/CT双时相显像对诊断主动脉移植物术后感染的临床价值

目的探讨18F-脱氧葡糖(FDG)PET/CT双时相显像(DTPI)在探测主动脉移植物感染(AGI)中的诊断价值。方法前瞻性纳入2014年10月至2021年10月临床初诊为可疑AGI并行PET/CT DTPI患者42例, 男35例, 女7例, 年龄(54±15)岁(22～79岁)。PET/CT图像质量分5级。对AGI诊断效能的评估采用半定量分析, 记录病灶早期显像最大标准化摄取值(SUVmax)、延迟显像SUVmax和DTPI保留指数(RI, 早期和延迟显像SUVmax变化的百分比)。以主动脉移植物感染管理协作组织(MAGIC)的AGI确诊依据为参考标准判断DTPI对AGI的诊断效能。结果 27例(64%, 27/42)患者确诊为AGI。AGI组RI值高于非AGI组[(26.7 ±18.9)%对(6.4 ±18.8)%, P<0.01]。以SUVmax≥6为最佳阈值, 常规早期PET/CT显像对AGI诊断的敏感度、特异性和准确性分别为88.9%、73.3%和83.3%。而DTPI延迟显像提高了对AGI诊断的敏感度(96.3%)和准确性(88.1%)。以DTPI RI ≥15%为最...     

基于18F-FDG PET/CT建立孤立性肺空洞的数学模型

目的利用Logistic回归分析建立18F-FDG PET/CT的数学模型用以诊断孤立性肺空洞的良恶性。方法分析2020年12月至2023年2月在吉林大学中日联谊医院PET/CT中心行18F-FDG PET/CT检查的孤立性肺空洞病例共92例, 其中男61例, 女31例, 对病例的一般资料及图像特征进行单因素分析及多因素二元Logistic回归分析, 筛选出与孤立性肺空洞良恶性相关的独立危险因素, 建立数学模型, 并通过比较受试者工作曲线下面积(AUC)比较该模型、CT、PET及PET/CT对孤立性肺空洞的诊断效能。结果 92例患者中良性32例(34.78%)、恶性60例(65.22%), 单因素分析结果提示以下因素在良恶性组间差异有统计学意义(P<0.05):病灶SUVmax值、病灶SUVmax/肝脏SUVmean、病灶SUVmax/脾脏SUVmean、病灶最大径、空洞壁不均匀、空洞壁分叶、胸膜牵拉、空洞内壁结节及偏心性空洞。通过Logistic回归分析构建数学模型为:y=exp(x)/[1+exp(x)], x=-2.022+0.419×(病灶SUVmax/脾脏SUVmean...     

Standardized Uptake Values from PET/MRI in Metastatic Breast Cancer: An Organ‐based Comparison With PET/CT

Quantitative standardized uptake values (SUVs) from fluorine‐18 (18F) fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) are commonly used to evaluate the extent of disease and response to treatment in breast cancer patients. Recently, PET/magnetic resonance imaging (MRI) has been shown to qualitatively detect metastases from various primary cancers with similar sensitivity to PET/CT. However, quantitative validation of PET/MRI requires assessing the reliability of SUVs from MR attenuation correction (MRAC) relative to CT attenuation correction (CTAC). The purpose of this retrospective study was to assess the utility of PET/MRI‐derived SUVs in breast cancer patients by testing the hypothesis that SUVs derived from MRAC correlate well with those from CTAC. Between August 2012 and May 2013, 35 breast cancer patients (age 37–78 years, 1 man) underwent clinical 18F‐FDG PET/CT followed by PET/MRI. One hundred seventy metastases were seen in 21 of 35 patients; metastases to bone in 16 patients, to liver in seven patients, and to nonaxillary lymph nodes in eight patients were sufficient for statistical analysis on an organ‐specific per patient basis. SUVs in the most FDG‐avid metastasis per organ per patient from PET/CT and PET/MRI were measured and compared using Pearson's correlations. Correlations between CTAC‐ and MRAC‐derived SUVmax and SUVmean in 31 metastases to bone, liver, and nonaxillary lymph nodes were strong overall (ρ = 0.80, 0.81). SUVmax and SUVmean correlations were also strong on an organ‐specific basis in 16 bone metastases (ρ = 0.76, 0.74), seven liver metastases (ρ = 0.85, 0.83), and eight nonaxillary lymph node metastases (ρ = 0.95, 0.91). These strong organ‐specific correlations between SUVs from PET/CT and PET/MRI in breast cancer metastases support the use of SUVs from PET/MRI for quantitation of 18F‐FDG activity.     

Use of Positron Emission Tomography in Assessing Hidden Extrathoracic Metastasis in Non Small Cell Lung Cancer

IntroductionPositron emission tomography combined with computed axial tomography (PET/CT) is used for staging non small cell lung cancer (NSCLC). This study aims to describe PET/CT findings of unsuspected extrathoracic metastasis when used in mediastinal evaluation of patients with apparently resectable NSCLC.Patients and methodProspective and concurrent study including all NSCLC patients between June 2004 and November 2006 who underwent PET/CT after considering them as candidates for surgery, with resectable disease after bronchoscopy, thorax and abdominal CT, brain CT and bone gammagraphy evaluation, if metastasis at these locations were suspected. Metastasis were confirmed histopathologically or assumed when they had a compatible evolution.ResultsA total of 91 patients with NSCLC underwent PET/CT. In 24 of them (26%) at least one suspicious extrathoracic uptake was seen. In 7 patients (7.7%) those uptakes were NSCLC extrathoracic metastasis hidden from conventional staging. In 3 of these cases (13.1%) extrathoracic uptakes corresponded to metacrhonous tumours or pre-malignant conditions. Benign lesions were found in 12 patients (13.1%), and in 2 cases (2.2%) the uptake origins were undetermined.ConclusionsPET/CT is a complementary diagnosis method for assessing hidden metastases which could modify the therapeutical approach in patients otherwise suitable for surgery.     

SPECT/CT定量分析对肿瘤患者脊柱颈胸段骨病变的诊断价值

目的 使用SPECT SUV进行定量评估,客观比较脊柱颈胸段骨关节炎和骨转移之间的99mTc-MDP示踪剂摄取,探讨SUV定量在骨关节炎和骨转移中的诊断价值.方法 回顾性分析在本院诊断为肿瘤的患者57例,用99mTc-MDP对其进行SPECT/CT骨显像.骨显像共发现187个高代谢颈胸椎病变,其中骨转移组143个,骨关...     

Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer

Background/Purpose The purpose of this study was to estimate the usefulness of positron emission tomography (PET) in deciding on strategies for the treatment of pancreatic cancer. The following two parameters were evaluated: the ability of PET to provide an estimation of the progression of pancreatic cancer, and the ability of PET to predict survival and the effect of chemoradiotherapy. Methods Forty-two patients underwent PET as part of the procedure for making a diagnosis of pancreatic tumors. The maximum standardized uptake value (SUVmax) levels were compared with clinicopathological factors and analyzed. Results PET provided a sensitivity of 87%, a specificity of 67%, and an overall accuracy of 85% for the diagnosis of pancreatic malignancy. Tumors with distant metastases showed significantly higher SUV levels than tumors without metastasis. In the patients who received chemoradiotherapy, the overall survival of the group in which SUVmax was less than 7.0 was better than that of the group in which SUVmax was more than 7.0. Conclusions We conclude that PET is a useful tool for determining pathological status and distant metastasis in pancreatic cancer, and for predicting the prognosis of patients receiving chemoradiotherapy.     

肝细胞癌18F-FDG PET/CT最大标准化摄取值的影响因素

目的 探讨肝细胞癌的18F-FDG PET/CT最大标准化摄取值（SUVmax）与临床病理特征的关系。方法 回顾性分析上海交通大学附属新华医院2011年7月至2015年1月间35例行肝细胞癌手术切除患者的18F-FDG PET/CT影像学资料,对可能影响原发肿瘤SUVmax的因素,包括性别、年龄、肿瘤直径、病理分级、微血管癌栓、TMN分期、T分期、N分期进行单因素分析和多元回归分析,对原发肿瘤SUVmax预测淋巴结转移的诊断效能采用受试者工作特征（ROC）曲线进行分析。结果 单因素分析显示SUVmax与肿瘤直径、病理分级、TMN分期、N分期明显相关（P < 0.05）,与性别、年龄、微血管癌栓、T分期无明显相关（P > 0.05）。多元线性回归分析显示,病理分级、肿瘤直径、N分期是SUVmax的独立影响因素（P < 0．05）。当原发肿瘤SUVmax界值为8.78时诊断效率最高,敏感度为75％,特异度为87％。结论 肝癌SUVmax与肿瘤分化程度、肿瘤大小、淋巴结转移显著相关,肝癌SUVmax对于淋巴结转移有预测价值。     

Detection of incidental colorectal tumours with 18F‐labelled 2‐fluoro‐2‐deoxyglucose positron emission tomography/computed tomography scans: results of a prospective study

Aim This study assessed the clinical significance of incidental colorectal 2‐fluoro‐2‐deoxyglucose (FDG) uptake using ¹⁸F‐FDG positron emission tomography/computed tomography (PET/CT) scans and evaluated the importance of colonoscopy when incidental colorectal FDG uptake was observed. Method A prospective study was designed and conducted at a single institution over a 2‐year period. In patients undergoing PET/CT scans, all with FDG uptake in the colorectum were assigned to have colonoscopy and biopsy. The value of PET/CT scanning was studied by comparison with the colonoscopy and biopsy results. Results Among 10 978 PET/CT scans, one or more focal uptakes of FDG in the colorectum were observed in 148 (1.35%) patients. In 136 valid patients, malignant colorectal tumours and polyps were found in 23.5% and 20.5%, respectively,, while the colon in the other 56% was normal. A higher false‐positive rate was found in the right colon compared with the distal colorectum (66.2%vs 36.7%, P = 0.004). A significant increase of the maximum standardized uptake (SUVmax) value was found among normal, polyps and cancer groups. Multivariate analysis revealed that SUVmax was the risk factor for predicting colorectal cancer or polyps and FDG uptake in the right colon was a negative predictive factor for finding cancers or polyps. Conclusions Our study proves the necessity of colonoscopy when incidental FDG uptake is found on PET/CT imaging. The false‐positive FDG uptake is more commonly observed in the right colon. Although the SUVmax value is higher in cancer patients, a high SUVmax value does not necessarily result in malignancies.     

Impact of F18-fluorodeoxyglycose positron emission tomography/computed tomography on the management of resectable pancreatic tumours

Background: Positron emission tomography/computed tomography (PET/CT) using F18‐fluorodeoxyglucose has been shown to be valuable in the management of malignant disease. The aim of this study is to investigate the impact of this technique on the management of patients with resectable pancreatic tumours. Methods: Thirty‐six patients with 37 potentially resectable pancreatic tumours on diagnostic CT imaging underwent PET/CT scans. Operative findings, histological reports and/or clinical follow‐up served as standard of reference. The impact of PET/CT on patient management was estimated by calculating the percentage of patients whose treatment plan was altered due to PET/CT. Results: Pancreatic adenocarcinoma was diagnosed in 30 patients, neuroendocrine tumours in 3, mass‐forming pancreatitis in 3 and serous cystadenoma in 1. The median standard uptake (max) value was 5.0 (range 2.2–12.0). Sensitivity and specificity of detecting extrapancreatic metastatic disease were 73% and 100%, respectively. Three occult liver metastases were detected at laparotomy following negative PET/CT. PET/CT findings influenced the management of 8 (22%) patients – 3 with liver metastases, 3 with bone metastases, 1 with lymph node metastases and 1 by identifying the benign appearance of the pancreatic tumour. Conclusion: PET/CT achieves a significant diagnostic impact in detecting extrapancreatic metastatic disease. F18‐fluorodeoxyglucose PET/CT appears to be useful in assessing suspicious pancreatic masses.